Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled TrialOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This randomized, double-blind, placebo-controlled trial tested whether manipulating the gut microbiota with antibiotics affects host metabolism in obese, prediabetic men. Participants received seven days of amoxicillin, vancomycin, or placebo. Researchers then measured bacterial composition alongside metabolic outcomes including insulin sensitivity, energy and substrate metabolism, systemic inflammation, gut permeability, and adipocyte size. Effects were assessed both immediately after treatment and at an 8-week follow-up.
Who was studied?
The study enrolled 57 obese, prediabetic men. All participants were randomized to one of three arms: amoxicillin, vancomycin, or placebo, taken for seven days. The abstract does not provide further demographic detail such as age range or geographic site.
What were the most important findings?
Vancomycin, but not amoxicillin, reduced bacterial diversity and decreased Firmicutes involved in short-chain fatty acid and bile acid metabolism, and this was accompanied by altered plasma and fecal metabolite concentrations. Adipose tissue gene expression of oxidative pathways increased with antibiotic treatment, while vancomycin specifically downregulated immune-related pathways in adipose tissue. Despite these microbial and gene-expression changes, antibiotics did not alter tissue-specific insulin sensitivity, energy or substrate metabolism, postprandial hormones and metabolites, systemic inflammation, gut permeability, or adipocyte size. At 8-week follow-up, energy harvest, adipocyte size, and whole-body insulin sensitivity remained unchanged even though microbial composition was still considerably altered.
What are the greatest implications of this study?
Short-term antibiotic-driven disruption of the adult gut microbiota, even when it measurably depletes Firmicutes and short-chain fatty acid and bile acid related metabolism, does not translate into clinically meaningful changes in metabolic health in obese humans. This suggests the adult microbiota may be more resilient to producing metabolic harm from brief antibiotic perturbation than some prior human and animal data implied. The persistence of altered microbial composition without a corresponding metabolic effect at 8 weeks also indicates that compositional change alone is not a reliable proxy for metabolic consequence in this population.